Sponsored by Celgene Corporation
This is a multicenter, open-label, Phase 1/2 study to determine the recommended dose and regimen of durvalumab in combination with lenalidomide (LEN) with or without dexamethasone (dex) in subjects with Newly diagnosed multiple myeloma (NDMM). The study will consist of a dose-finding phase as well as a parallel dose-expansion phase to determine the optimal regimen.
Study Start Date: April 2016
Estimated Completion Date: August 2024
Specialties: Internal Medicine: Hematology/Oncology Nursing: Hematology/Oncology Oncology: Leukemia/Lymphoma Medical Student: Hematology/Oncology Physician Assistant: Hematology/Oncology
AND have measurable disease by protein electrophoresis analyses as defined by the following:
Get your trial in front of 1000s of physicians and patients.
Visit ClinicalTrialsLocator.com to find out how you can feature this clinical trial.
Don't Have Account? Sign Up here.
Enter your email address and a password reset email will be sent to you.
Please submit one of the following:
— Action Required —
Your browser is currently blocking ads. We depend on ad sponsorships in order to keep this site free to the healthcare provider community. Help us keep this site free by turning off your ad blocker.
Turn Off Ad Blocker
We have detected that you are currently blocking ads. We kindly ask that you enable ads when visiting our site. We depend on ad sponsorships in order to keep this site free to the healthcare provider community.